David B. Donner

University of California, San Francisco

Papers

1

Total Citations

3

H-Index

1

About

Dr. David B. Donner is a pioneering oncologist whose research focuses on cholangiocarcinoma, particularly the development of patient-derived organoids for personalized medicine. His most cited work, a 2020 study on intrahepatic cholangiocarcinoma (ICC), addresses the urgent need for novel therapies in a disease where standard treatment yields a median survival under one year. By creating organoid models from patient tumors, Dr. Donner enables high-throughput drug screening to identify effective, individualized treatments. This approach tackles the challenge of few targetable mutations in ICC, offering a path beyond conventional chemotherapy. With 3 citations, this landmark paper underscores his impact in advancing precision oncology for rare, aggressive cancers. His contributions bridge the gap between laboratory discovery and clinical application, providing hope for patients with limited options. Dr. Donner’s work exemplifies how innovative modeling can transform cancer care, making him a key figure in the fight against biliary tract malignancies.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma.
3 citations · 2020
📈 Most Prolific Year: 2020 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: University of California, San Francisco

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago